Electrographic flow-guided ablation appears to benefit redo patients with nonparoxysmal AF

Source: healio.com

Electrographic flow-guided ablation was associated with improvement in freedom from atrial fibrillation at 1 year compared with standard pulmonary vein isolation in patients with nonparoxysmal AF requiring a redo ablation, data showed.

The trial included patients with persistent or long-standing persistent AF who required a redo catheter ablation, Vivek Y.…

Continue Reading

The FLOW-AF multicenter, randomized controlled trial shows Ablacon’s Electrographic Flow® (EGF®) Mapping software (Ablamap®) results in improved ablation outcomes in persistent atrial fibrillation

Source: PRNewswire

MENLO PARK, Calif., Feb. 3, 2023 /PRNewswire/ — Ablacon, Inc., an Ajax Health and Zeus Health-backed developer of an innovative mapping system to guide the treatment of atrial fibrillation (AF), announced today the 12-month results from the FLOW-AF trial (NCT04473963). The data were presented by Dr. Vivek…

Continue Reading

$30 Million Series B Financing and Expansion of Scientific Advisory Board

Ablacon, Inc., an Ajax Health-backed company, announced the close of a $30 million Series B financing, with Zeus Health joining as new lead investor.  Ablacon also announced the addition of Dr. David Haines, Professor of Cardiovascular Medicine at Oakland University William Beaumont School of Medicine and Director of the Heart Rhythm Center at Beaumont Health, Royal Oak, MI, to the company’s scientific advisory board (SAB).…

Continue Reading

Ablacon Announces Release of New and Improved Ablamap Technology Under Existing CE Mark

MENLO PARK, Calif., Sept. 10, 2019 /PRNewswire/ — Ablacon, Inc. (www.ablacon.com), an Ajax Health-funded company, announced today the release of an updated version of its Ablamap technology under the company’s existing CE Mark.  The new update includes an enhanced physician experience and user interface, along with significantly faster processing times leading to improved procedural efficiency. …

Continue Reading

Ablacon Announces Closing of a $10 Million Venture Debt Facility and $2 Million Equity Investment from Western Technology Investment; Josef Koblish and Melissa Kong to Join the Company

MENLO PARK, Calif., July 23, 2019 /PRNewswire/ — Ablacon Inc. announced today that it has entered into a $10 millionventure debt facility with Western Technology Investment (WTI). The debt is accompanied by a $2 million equity investment in the Company. This financing will help fund Ablacon’s first multicenter randomized clinical trial for Ablamap, an advanced mapping system for patients with atrial fibrillation.…

Continue Reading

Forbes lists Ablacon “25 Top Machine Learning Startups To Watch In 2019”

From powering personalized career sites that recommend open positions that are ideal for a given candidate based on their capabilities as eightfold.ai does today, to scaling the complexity and volume of machine learning algorithms, so they’re more accessible as DataRobot does, machine learning startups are taking on many of business’ most significant challenges.…

Continue Reading